Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer

20Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

Albumin nanoparticles are considered to be an effective way to load water-insoluble anticancer drugs and target tumors via the gp60-mediated pathway. Herein, we fabricated an albumin nanoparticle formulation for co-loading paclitaxel (PTX) and curcumin (CCM), both of which have prominent anticancer efficacy, via nanoparticle albumin-bound (NabTM) technology using high-pressure homogenization. The PTX/CCM co-bound albumin nanoparticles (PTX/CCM Alb-NPs) had a slightly greater particle size of ~250 nm than that of plain PTX Alb-NPs and CCM Alb-NPs (~234 and ~134 nm, respectively), with spherical surface morphology and stable size maintenance. However, the zeta potential of PTX/CCM Alb-NPs (ca. −30 mV) was not significantly different from that of PTX or CCM Alb-NPs. The loaded PTX and CCM were released gradually from the PTX/CCM Alb-NPs over ~24 h (97.7 ± 1.7% and 76.2 ± 0.5%, respectively). Furthermore, PTX/CCM Alb-NPs appeared to be efficiently internalized into Mia Paca-2 cells and exhibited a 71% increased IC50versus PTX Alb-NPs in terms of cytotoxicity to Mia Paca-2 cells. These results suggest that PTX/CCM Alb-NPs are a new potential anticancer agent for combination therapy.

Cite

CITATION STYLE

APA

Kim, B., Lee, C., Lee, E. S., Shin, B. S., & Youn, Y. S. (2016). Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer. Asian Journal of Pharmaceutical Sciences, 11(6), 708–714. https://doi.org/10.1016/j.ajps.2016.05.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free